Assess Functional Outcomes in Anemic, Critically Ill, Trauma Patients When Taking Epoetin Alfa

Inclusion Criteria: * ICU admission secondary to a blunt multi-system traumatic injury * A leg or pelvic fracture must be one of the injuries sustained * Male or female * Age between 18 and 55 years * Hemoglobin \<=12g/dL at study entry * An expected ICU stay \>=2 days * Glascow Coma Scale (GCS) score must be \>= 13 at hospital admission or within 24 hours of admission * Documented ability to function independently prior to this hospitalization as determined by a subject or proxy interview using the Karnofsky Performance scale and having a score \>=80 * Subjects (or appropriate legal representative) must sign the informed consent form after the nature of the study has been fully explained * Female subjects that can become pregnant must use an adequate contraceptive method (e.g., abstinence, intrauterine device, oral contraceptives, barrier device with spermicide, or surgical sterilization) during study * Subjects must be literate in their native language in order to complete written self-assessments during the post-hospital discharge phase Exclusion Criteria: * Acute burns * Traumatic Brain Injury (TBI) with admission GCS \<= 12 and/or spinal cord injury * Cause of injury secondary to a fall from a standing position * Trauma victims transferred into the participating institution \> 8 hours post injury * Subjects not expected to survive 12 months given their injuries and/or pre-existing, uncorrectable medical condition * Chronic renal failure on dialysis * Significant hematological disease * All subjects expected to undergo chemotherapy during the course of treatment * A current diagnosis of uncontrolled hypertension * New onset seizures (within three months) or seizures not controlled by medication prior to admission * Gustillo III fracture, open pelvic fracture, traumatic amputation * Prior history or diagnosis of deep vein thrombosis (DVT), pulmonary embolism (PE), or genetic coagulation abnormality * Pregnancy or lactation * Refusal to accept blood transfusion * Received an experimental drug or used an experimental medical device within 30 days prior to the planned start of treatment * Treatment with any recombinant human erythropoietin within 30 days prior to enrollment - Known hypersensitivity to human albumin or mammalian cell-derived products or epoetin alfa * Employees of the investigator or study center with direct involvement in the proposed study or other studies under the direction of that investigator or study center